1. Schall Law Firm investigating potential securities law violations by TLX. 2. Telix faced SEC subpoena regarding disclosures for prostate cancer treatments. 3. TLX stock dropped over 10.4% following the SEC inquiry announcement. 4. Investors encouraged to join litigation for possible losses suffered. 5. Law firm specializes in securities class action lawsuits.
The SEC investigation raises significant concerns about transparency, affecting investor confidence. Similar historical cases often lead to prolonged stock declines.
The ongoing investigation could materially impact TLX's valuation and investor sentiment, making it crucial for stakeholders.
Short-term effects are likely due to immediate investor reactions to the news. Long-term impact will depend on the investigation outcome and any potential recovery strategies.
LOS ANGELES, Aug. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Telix disclosed on July 22, 2025, that it had received a subpoena from the SEC "seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates." Based on this news, Telix ADRs fell by more than 10.4% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tlx-investors-have-opportunity-to-join-telix-pharmaceuticals-limited-fraud-investigation-with-the-schall-law-firm-302535452.html
SOURCE The Schall Law Firm